Bioventus (NASDAQ:BVS) Shares Down 6.8% – What’s Next?

Bioventus Inc. (NASDAQ:BVS) shares fell 6.8% on Wednesday . The stock traded as low as $8.60 and last traded at $8.4050. 334,402 shares traded hands during trading, a decline of 17% from the average session volume of 403,737 shares. The stock had previously closed at $9.02.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on BVS. CJS Securities began coverage on shares of Bioventus in a report on Friday, March 27th. They set a “market outperform” rating and a $14.00 price objective for the company. Cantor Fitzgerald raised shares of Bioventus to a “strong-buy” rating in a report on Wednesday, March 4th. Barrington Research reissued an “outperform” rating and set a $14.00 price objective on shares of Bioventus in a report on Friday, May 22nd. Finally, Craig Hallum boosted their price objective on shares of Bioventus from $15.00 to $16.00 and gave the company a “buy” rating in a report on Friday, March 6th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Bioventus presently has an average rating of “Buy” and an average price target of $14.00.

Bioventus Price Performance

The firm’s 50-day moving average is $9.68 and its 200-day moving average is $8.51. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.69 and a quick ratio of 1.13. The company has a market capitalization of $746.85 million, a P/E ratio of 21.80, a price-to-earnings-growth ratio of 1.18 and a beta of 0.72.

Bioventus (NASDAQ:BVS) last announced its earnings results on Wednesday, May 6th. The company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.06. The company had revenue of $132.09 million during the quarter. Bioventus had a net margin of 4.94% and a return on equity of 29.97%. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. Analysts predict that Bioventus Inc. will post 0.79 EPS for the current fiscal year.

Insider Transactions at Bioventus

In related news, Director Michelle Mcmurry-Heath sold 12,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $8.79, for a total transaction of $105,480.00. Following the completion of the sale, the director directly owned 44,997 shares in the company, valued at approximately $395,523.63. The trade was a 21.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 33.00% of the company’s stock.

Institutional Trading of Bioventus

Large investors have recently added to or reduced their stakes in the business. Bank of America Corp DE boosted its position in shares of Bioventus by 40.3% in the first quarter. Bank of America Corp DE now owns 86,057 shares of the company’s stock worth $786,000 after purchasing an additional 24,723 shares during the period. Engine Capital Management LP bought a new position in shares of Bioventus in the first quarter worth approximately $2,876,000. Quantinno Capital Management LP boosted its position in shares of Bioventus by 119.6% in the first quarter. Quantinno Capital Management LP now owns 72,023 shares of the company’s stock worth $658,000 after purchasing an additional 39,222 shares during the period. Lazard Asset Management LLC boosted its position in shares of Bioventus by 12.9% in the first quarter. Lazard Asset Management LLC now owns 305,517 shares of the company’s stock worth $2,789,000 after purchasing an additional 35,008 shares during the period. Finally, Sei Investments Co. boosted its position in shares of Bioventus by 160.7% in the first quarter. Sei Investments Co. now owns 289,648 shares of the company’s stock worth $2,644,000 after purchasing an additional 178,539 shares during the period. 62.94% of the stock is currently owned by institutional investors.

About Bioventus

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.